Infant RSV Protection Estimates From Maternal Vaccination and Nirsevimab Receipt

CDC National Immunization Survey–Adult COVID Module data provides monthly estimates of infant protection against Respiratory Syncytial Virus (RSV). Estimates are based on parent-reported receipt of nirsevimab or maternal RSV vaccination from a random-digit-dial cellular telephone survey of households. Data were reported by females aged 18-49 years with infants under 8 months born since April 1, 2024.

Use Cases

• Analyze trends in infant RSV protection over the 'Timeframe' column using 'Estimate' and '95% Confidence Interval'.
• Compare 'Indicator Category' values like maternal vaccination versus nirsevimab receipt across different 'Geographic Label' regions.
• Assess data reliability by examining 'Sample Size' and 'Suppressed Flag' for estimates with high uncertainty.
• Model the relationship between 'Indicator Variable' categories and 'Estimate' values to understand factors influencing protection rates.

Strengths

• Includes statistical reliability metrics via '95% Confidence Interval' and 'Sample Size' columns.
• Provides geographic breakdowns through the 'Geographic Label' column.
• Data is sourced from an ongoing, established federal survey (NIS–ACM).

Limitations

• All estimates rely on parent-reported data, which is subject to recall bias.
• Sample size and row count are unknown, limiting assessment of statistical power.
• Data is restricted to infants born after April 1, 2024, limiting historical comparison.

Provenance

Source

National Immunization Survey–Adult COVID Module (NIS–ACM) via data.cdc.gov.

Collection Method

Random-digit-dial cellular telephone survey of households with adults 18 years and older.

Time Range

Monthly data for infants born since April 1, 2024.

Freshness

Updated monthly, with last update on 2025-05-16.

Geography

United States, with breakdowns available via 'Geographic Label'.